|
1
|
Al-Brahim N and Asa SL: Papillary thyroid
carcinoma: An overview. Arch Pathol Lab Med. 130:1057–1062.
2006.PubMed/NCBI
|
|
2
|
Nikiforova MN and Nikiforov YE: Molecular
genetics of thyroid cancer: Implications for diagnosis, treatment
and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Enewold L, Zhu K, Ron E, Marrogi AJ,
Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer
incidence in the United States by demographic and tumor
characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev.
18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang LY and Ganly I: Nodal metastases in
thyroid cancer: Prognostic implications and management. Future
Oncol. 12:981–994. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Asimakopoulos P, Nixon IJ and Shaha AR:
Differentiated and medullary thyroid cancer: Surgical management of
cervical lymph nodes. Clin Oncol (R Coll Radiol). 29:283–289. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grant CS: Recurrence of papillary thyroid
cancer after optimized surgery. Gland Surg. 4:52–62.
2015.PubMed/NCBI
|
|
8
|
Giusca SE, Amalinei C, Lozneanu L, Ciobanu
Apostol D, Andriescu EC, Scripcariu A, Balan R, Avadanei ER and
Căruntu ID: Heterogeneous periostin expression in different
histological variants of papillary thyroid carcinoma. Biomed Res
Int. 2017:87013862017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spiegel S and Milstien S: Functions of the
multifaceted family of sphingosine kinases and some close
relatives. J Biol Chem. 282:2125–2129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spiegel S and Milstien S:
Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol
Cell Biol. 4:397–407. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Green JA, Suzuki K, Cho B, Willison LD,
Palmer D, Allen CD, Schmidt TH, Xu Y, Proia RL, Coughlin SR and
Cyster JG: The sphingosine 1-phosphate receptor S1P2
maintains the homeostasis of germinal center B cells and promotes
niche confinement. Nat Immunol. 12:672–680. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malavaud B, Pchejetski D, Mazerolles C, de
Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier
O: Sphingosine kinase-1 activity and expression in human prostate
cancer resection specimens. Eur J Cancer. 46:3417–3424. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bayerl MG, Bruggeman RD, Conroy EJ, Hengst
JA, King TS, Jimenez M, Claxton DF and Yun JK: Sphingosine kinase 1
protein and mRNA are overexpressed in non-Hodgkin lymphomas and are
attractive targets for novel pharmacological interventions. Leuk
Lymphoma. 49:948–954. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
French KJ, Schrecengost RS, Lee BD, Zhuang
Y, Smith SN, Eberly JL, Yun JK and Smith CD: Discovery and
evaluation of inhibitors of human sphingosine kinase. Cancer Res.
63:5962–5969. 2003.PubMed/NCBI
|
|
15
|
Van Brocklyn JR, Jackson CA, Pearl DK,
Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression
correlates with poor survival of patients with glioblastoma
multiforme: Roles of sphingosine kinase isoforms in growth of
glioblastoma cell lines. J Neuropathol Exp Neurol. 64:695–705.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu YJ, You H, Tan JX, Li F, Qiu Z, Li HZ,
Huang HY, Zheng K and Ren GS: Overexpression of sphingosine kinase
1 is predictive of poor prognosis in human breast cancer. Oncol
Lett. 14:63–72. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Tian Z, Qin H, Li N, Zhou X, Li J,
Ni B and Ruan Z: High expression of sphingosine kinase 1 is
associated with poor prognosis in nasopharyngeal carcinoma. Biochem
Biophys Res Commun. 460:341–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tran B, Roshan D, Abraham E, Wang L,
Garibotto N, Wykes J, Campbell P and Ebrahimi A: An analysis of the
American Joint Committee on Cancer 8th edition T staging system for
papillary thyroid carcinoma. J Clin Endocrinol Metab.
103:2199–2206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Schlumberger M,
Sawka AM, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen L, Zhang W, Yan W, Han L, Zhang K,
Shi Z, Zhang J, Wang Y, Li Y, Yu S, et al: The putative tumor
suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in
glioma. Carcinogenesis. 33:2276–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang HG, Cao B, Zhang LX, Song N, Li H,
Zhao WZ, Li YS, Ma SM and Yin DJ: KLF2 inhibits cell growth via
regulating HIF-1a/Notch-1 signal pathway in human colorectal cancer
HCT116 cells. Oncol Rep. 38:584–590. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nguyen QT, Lee EJ, Huang MG, Park YI,
Khullar A and Plodkowski RA: Diagnosis and treatment of patients
with thyroid cancer. Am Health Drug Benefits. 8:30–40.
2015.PubMed/NCBI
|
|
23
|
Popadich A, Levin O, Lee JC, Smooke-Praw
S, Ro K, Fazel M, Arora A, Tolley NS, Palazzo F, Learoyd DL, et al:
A multicenter cohort study of total thyroidectomy and routine
central lymph node dissection for cN0 papillary thyroid cancer.
Surgery. 150:1048–1057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hartl DM, Mamelle E, Borget I, Leboulleux
S, Mirghani H and Schlumberger M: Influence of prophylactic neck
dissection on rate of retreatment for papillary thyroid carcinoma.
World J Surg. 37:1951–1958. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bae GE, DO SI, Kim K, Park JH, Cho S and
Kim HS: Increased sphingosine kinase 1 expression predicts distant
metastasis and poor outcome in patients with colorectal cancer.
Anticancer Res. 39:663–670. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bouquerel P, Gstalder C, Müller D, Laurent
J, Brizuela L, Sabbadini RA, Malavaud B, Pyronnet S, Martineau Y,
Ader I and Cuvillier O: Essential role for SphK1/S1P signaling to
regulate hypoxia-inducible factor 2a expression and activity in
cancer. Oncogenesis. 5:e2092016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang
S, Liu L, Chen T, Li J, Tu H and He X: Sphingosine kinase 1
promotes tumour cell migration and invasion via the S1P/EDG1 axis
in hepatocellular carcinoma. Liver Int. 32:331–338. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan J, Tao YF, Zhou Z, Cao BR, Wu SY,
Zhang YL, Hu SY, Zhao WL, Wang J, Lou GL, et al: An novel role of
sphingosine kinase-1 (SPHK1) in the invasion and metastasis of
esophageal carcinoma. J Transl Med. 9:1572011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang K, Chen H, Wu G, Chen K and Yang H:
High expression of SPHK1 in sacral chordoma and association with
patients' poor prognosis. Med Oncol. 31:2472014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xia P, Wang L, Moretti PA, Albanese N,
Chai F, Pitson SM, D'Andrea RJ, Gamble JR and Vadas MA: Sphingosine
kinase interacts with TRAF2 and dissects tumor necrosis
factor-alpha signaling. J Biol Chem. 277:7996–8003. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wattenberg BW, Pitson SM and Raben DM: The
sphingosine and diacylglycerol kinase superfamily of signaling
kinases: Localization as a key to signaling function. J Lipid Res.
47:1128–1139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pitson SM, Xia P, Leclercq TM, Moretti PA,
Zebol JR, Lynn HE, Wattenberg BW and Vadas MA:
Phosphorylation-dependent translocation of sphingosine kinase to
the plasma membrane drives its oncogenic signalling. J Exp Med.
201:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ogretmen B: Sphingolipid metabolism in
cancer signalling and therapy. Nat Rev Cancer. 18:33–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nema R, Vishwakarma S, Agarwal R, Panday
RK and Kumar A: Emerging role of sphingosine-1-phosphate signaling
in head and neck squamous cell carcinoma. Onco Targets Ther.
9:3269–3280. 2016.PubMed/NCBI
|
|
35
|
Pyne S and Pyne NJ: Sphingosine
1-phosphate signalling in mammalian cells. Biochem J. 349:385–402.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Safadi-Chamberlain F, Wang LP, Payne SG,
Lim CU, Stratford S, Chavez JA, Fox MH, Spiegel S and Summers SA:
Effect of a membrane-targeted sphingosine kinase 1 on cell
proliferation and survival. Biochem J. 388:827–834. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li W, Yu CP, Xia JT, Zhang L, Weng GX,
Zheng HQ, Kong QL, Hu LJ, Zeng MS, Zeng YX, et al: Sphingosine
kinase 1 is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 15:1393–1399. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li J, Guan HY, Gong LY, Song LB, Zhang N,
Wu J, Yuan J, Zheng YJ, Huang ZS and Li M: Clinical significance of
sphingosine kinase-1 expression in human astrocytomas progression
and overall patient survival. Clin Cancer Res. 14:6996–7003. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rosa R, Marciano R, Malapelle U, Formisano
L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio
S, et al: Sphingosine kinase 1 overexpression contributes to
cetuximab resistance in human colorectal cancer models. Clin Cancer
Res. 19:138–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang F and Wu Z: Sphingosine kinase 1
overexpression is associated with poor prognosis and oxaliplatin
resistance in hepatocellular carcinoma. Exp Ther Med. 15:5371–5376.
2018.PubMed/NCBI
|
|
41
|
Brizuela L, Ader I, Mazerolles C, Bocquet
M, Malavaud B and Cuvillier O: First evidence of sphingosine
1-phosphate lyase protein expression and activity downregulation in
human neoplasm: Implication for resistance to therapeutics in
prostate cancer. Mol Cancer Ther. 11:1841–1851. 2012. View Article : Google Scholar : PubMed/NCBI
|
